Northland Capital Markets analyst Carl Byrnes maintains BioLife Solns (NASDAQ:BLFS) with a Outperform and raises the price target from $26 to $28.
Northland Capital Markets Maintains Outperform on BioLife Solns, Raises Price Target to $28
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.